| European Federation of Internal Medicine

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News

Type: News Feed

Human medicines European public assessment report (EPAR): Tryngolza, olezarsen, Date of authorisation: 17/09/2025, Status: Authorised

Submitted by Anonymous (not verified) on 17 October 2025 - 16:50

Human medicines European public assessment report (EPAR): Tryngolza, olezarsen, Date of authorisation: 17/09/2025, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Tryngolza, olezarsen, Date of authorisation: 17/09/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Izamby, denosumab, Date of authorisation: 26/06/2025, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 17 October 2025 - 16:32

Human medicines European public assessment report (EPAR): Izamby, denosumab, Date of authorisation: 26/06/2025, Revision: 1, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Izamby, denosumab, Date of authorisation: 26/06/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Mynzepli, aflibercept, Date of authorisation: 18/08/2025, Status: Authorised

Submitted by Anonymous (not verified) on 17 October 2025 - 16:15

Human medicines European public assessment report (EPAR): Mynzepli, aflibercept, Date of authorisation: 18/08/2025, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Mynzepli, aflibercept, Date of authorisation: 18/08/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 29, Status: Authorised

Submitted by Anonymous (not verified) on 17 October 2025 - 15:00

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 29, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Qoyvolma, ustekinumab, Date of authorisation: 02/06/2025, Revision: 2, Status: Authorised

Submitted by Anonymous (not verified) on 17 October 2025 - 14:45

Human medicines European public assessment report (EPAR): Qoyvolma, ustekinumab, Date of authorisation: 02/06/2025, Revision: 2, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Qoyvolma, ustekinumab, Date of authorisation: 02/06/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Kavigale, sipavibart, Date of authorisation: 20/01/2025, Revision: 2, Status: Authorised

Submitted by Anonymous (not verified) on 17 October 2025 - 14:05

Human medicines European public assessment report (EPAR): Kavigale, sipavibart, Date of authorisation: 20/01/2025, Revision: 2, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Kavigale, sipavibart, Date of authorisation: 20/01/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Otulfi, ustekinumab, Date of authorisation: 25/09/2024, Revision: 4, Status: Authorised

Submitted by Anonymous (not verified) on 17 October 2025 - 14:00

Human medicines European public assessment report (EPAR): Otulfi, ustekinumab, Date of authorisation: 25/09/2024, Revision: 4, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Otulfi, ustekinumab, Date of authorisation: 25/09/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Sapropterin Dipharma, sapropterin, Date of authorisation: 16/02/2022, Revision: 6, Status: Authorised

Submitted by Anonymous (not verified) on 17 October 2025 - 13:35

Human medicines European public assessment report (EPAR): Sapropterin Dipharma, sapropterin, Date of authorisation: 16/02/2022, Revision: 6, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Sapropterin Dipharma, sapropterin, Date of authorisation: 16/02/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Tecartus, brexucabtagene autoleucel, Date of authorisation: 14/12/2020, Revision: 14, Status: Authorised

Submitted by Anonymous (not verified) on 17 October 2025 - 13:30

Human medicines European public assessment report (EPAR): Tecartus, brexucabtagene autoleucel, Date of authorisation: 14/12/2020, Revision: 14, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Tecartus, brexucabtagene autoleucel, Date of authorisation: 14/12/2020, Revision: 14, Status: Authorised

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Human medicines European public assessment report (EPAR): Tryngolza, olezarsen, Date of authorisation: 17/09/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Izamby, denosumab, Date of authorisation: 26/06/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Mynzepli, aflibercept, Date of authorisation: 18/08/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Qoyvolma, ustekinumab, Date of authorisation: 02/06/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Kavigale, sipavibart, Date of authorisation: 20/01/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Otulfi, ustekinumab, Date of authorisation: 25/09/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Sapropterin Dipharma, sapropterin, Date of authorisation: 16/02/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Tecartus, brexucabtagene autoleucel, Date of authorisation: 14/12/2020, Revision: 14, Status: Authorised

Newsletters

Latest Newsletters

You are here

Newsletters

Latest Newsletters